Abstracts tagged "Biomarkers"

Abstract Number: 2371 • ACR Convergence 2023
Plasma and Urine Cytokine Profiles in Active ANCA-Associated Vasculitis
Salem Almaani¹, Huijuan Song², Stacy Ardoin³, Lynn Fussner² and Brad Rovin², ¹Ohio State University Medical Center, Columbus, OH, ²Ohio State University, Columbus, OH, ³Nationwide Children's Hospital, Columbus, OH
Background/Purpose: ANCA-associated vasculitis (AAV) is a multisystem autoimmune disease that often affects the kidneys. It is unclear why some patients with AAV have kidney involvement…
Abstract Number: 2586 • ACR Convergence 2023
A Novel Blood-Based Assay Differentiates Seropositive and Seronegative Rheumatoid Arthritis from Healthy Individuals and Those with Other Inflammatory Diseases or Osteoarthritis
Peter C. Taylor¹, Jenya Antonova², Jennifer Geis³, Katharine Dilger³, David Chernoff⁴, Diana Abdueva³, Nancy Shadick⁵ and Michael Weinblatt⁶, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Compass Strategy and Research, Inc., San Francisco, CA, ³Aqtual Inc., Hayward, CA, ⁴Chernoff Consulting, Sausalito, CA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Harvard Medical School, Waban, MA
Background/Purpose: Non-invasive differentiation of seropositive and seronegative rheumatoid arthritis (RA) from other conditions has been limited in the current practice. We aimed to evaluate the…
Abstract Number: 0149 • ACR Convergence 2023
Impacts of Social Determinants of Health and the Immune System in Adults with Acute-to-Chronic Low Back Pain: An Observational Study
Colleen Burke¹, Michael Brown², Kenneth Taylor², Stephanie Danyluk², Kelley Seebeck² and Adam Goode³, ¹Duke University School of Medicine, Chapel Hill, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Durham, NC
Background/Purpose: Chronic low back pain (cLBP) is common worldwide yet poorly understood due to the combination of biological, psychological, and sociological factors. An individual's social…
Abstract Number: 0546 • ACR Convergence 2023
Markers of Oxidative Stress in Systemic Lupus Erythematosus Patients with Nephritis
Lu Liu, Karina de Leeuw, Suzanne Arends, Berber Doornbos-van der Meer, Harry van Goor and Johanna Westra, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Lupus nephritis (LN) is regarded as one of the most severe manifestations of systemic lupus erythematosus (SLE). This inflammation in the kidneys may lead…
Abstract Number: 0647 • ACR Convergence 2023
Prevalence and Risk Factors of Left Ventricular Diastolic Dysfunction in Systemic Sclerosis: Insights from New Echocardiographic Parameters
Irene Carrión-Barberà¹, Laura Triginer², Laura Tío², Anna Pros³, Laia Belarte Tornero¹, Sara Valdivielso More¹, Sonia Ruiz Bustillo¹, Joan Vime Jubany¹, Nuria Farré López¹ and Ronald Morales Murillo¹, ¹Hospital del Mar, Barcelona, Spain, ²Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain, ³Department of Rheumatology, Hospital del Mar, Barcelona, Spain
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease that can affect multiple organs including the heart. Primary heart involvement in SSc refers…
Abstract Number: 0867 • ACR Convergence 2023
Pentosan Polysulfate Sodium, a Glycosaminoglycan Mimetic Demonstrates Durable Effects on Pain, Function and Joint Structure in Canine Naturally Occurring Osteoarthritis
Ravi Krishnan¹, Catherine Stapledon², Christian Reiter², Stewart Ryan³, Sebastien Bauquier³ and Thierry Beths³, ¹Paradigm Biopharmaceuticals, Adelaide, Australia, ²Paradigm Biopharmaceuticals, Melbourne, Australia, ³U-Vet Werribee Animal Hospital, University of Melbourne, Melbourne, Australia
Background/Purpose: Pentosan Polysulfate sodium (PPS) is a semi-synthetic polysaccharide and a glycosaminoglycan mimetic. The multiple actions of PPS involve anti-inflammatory effects via inhibition of NF-κB;…
Abstract Number: 1163 • ACR Convergence 2023
Anti-melanoma Differentiation Associated Gene 5 (Anti-MDA5) Antibody Dermatomyositis: Clinical Features and Outcome in a Racially Diverse Patient Cohort
Sai Koyoda¹, Dawn Wahezi², Xianhong Xie³, Anand Kumthekar⁴, Clement Tagoe³ and Bibi Ayesha⁵, ¹Essen Medical Center, Rahway, NJ, ²Children's Hospital at Montefiore, New Rochelle, NY, ³Albert Einstein College of Medicine, Bronx, NY, ⁴Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁵Montefiore Medical Center, Bronx, NY
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody dermatomyositis typically expresses rapidly progressing interstitial lung disease (RP-ILD) and ulcerative skin lesions, with or without muscle involvement.…
Abstract Number: 1456 • ACR Convergence 2023
Systematic Review of Effects of Systemic Lupus Erythematosus on Brain Structure and Structural Connectivity and Its Relationship with Cognitive Dysfunction Through an Advanced Neuroimaging Lens
Ibrahim Mohamed¹, Tala El Tal², santiago arciniegas³, Stephanie Fevrier⁴, justine ledochowski⁵ and Andrea Knight⁴, ¹The Hospital for Sick Children, Brampton, ON, Canada, ²Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Department of Psychology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Cognitive dysfunction (CD) is highly prevalent in systemic lupus erythematosus (SLE), and advanced structural magnetic resonance imaging (MRI) has revealed brain abnormalities in patients…
Abstract Number: 1698 • ACR Convergence 2023
High-throughput Proteomics Identities a Spectrum of Novel Serum Biomarkers of Lupus Nephritis
Huihua Ding, Yiwei Shen, Min Dai and Nan Shen, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Navigating the molecular complexity of lupus nephritis (LN), a heterogeneous autoimmune disorder, poses challenges to biomarker discovery. This study addresses these challenges through an…
Abstract Number: 1864 • ACR Convergence 2023
Quantifying Inflammation: A Novel In-Vivo Total Body PET Imaging Tool to Determine the Kinetics of the Degree of Changes in Inflammation in Different Time Points
Siba Raychaudhuri¹, Sanchita Raychaudhuri², Naveen Chandrasekar³, Christine Abria³, Sneha Banerjee³, Smriti K Raychaudhuri³ and Abhijit Chaudhari², ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²UC Davis School of Medicine, Sacramento, CA, ³VA Sacramento Medical Center, Mather, CA
Background/Purpose: Collagen‐induced arthritis (CIA) mouse model is one of the best recognized animal model for autoimmune diseases. In this model clinical methods of evaluating inflammation…
Abstract Number: 2336 • ACR Convergence 2023
Identification of Urine Metabolites Linked to Disease Activity That Are Modulated by Anifrolumab in a Phase 2 LN Trial Using Untargeted Metabolomics Analysis
David Jayne¹, Eduardo Mysler², Zahir Amoura³, Patrick Gavin⁴, Erik Allman⁴, Cristina Di Poto⁴, Xiang Tian⁴, Sonja Hess⁴, Eszter Csomor⁵, Philip Brohawn⁴, Daniel Muthas⁵, Adam Platt⁶, Hussein Al-Mossawi⁶, Catharina Lindholm⁵ and Nicola Ferrari⁶, ¹University of Cambridge, Cambridge, United Kingdom, ²Organizacion Medica de Investigacion, Buenos Aires, Argentina, ³French National Reference Center for SLE, Hôpital La Pitié-Salpêtrière, Paris, France, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁶BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: LN is a severe complication of SLE, affecting 21%–48% of patients.1 Development of noninvasive diagnostic tests for LN is ongoing; urinary biomarkers have good…
Abstract Number: 2374 • ACR Convergence 2023
Torque Teno Virus as a Potential Biomarker for Assessment of Immunocompetence in Patients with ANCA-associated Vasculitis
Balazs Odler¹, Regina Riedl¹, Jacinta Lee², Laura Cooney³, Peter Merkel⁴, William St.Clair⁵, Duvuru Geetha⁶, Paul Monach⁷, David Jayne², Rona Smith², Paul A. Lyons², Mark Little⁸, Salem Almaani⁹, Alexander Rosenkranz¹, Ulrich Specks¹⁰, John Stone¹¹ and Andreas Kronbichler¹², ¹Medical University of Graz, Graz, Austria, ²University of Cambridge, Cambridge, United Kingdom, ³Immune Tolerance Network, Seattle, WA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Duke University Medical Center, Durham, NC, ⁶Johns Hopkins University, Baltimore, MD, ⁷VA Boston Healthcare System, Boston, MA, ⁸Trinity College Dublin, Dublin, Ireland, ⁹Ohio State University Medical Center, Columbus, OH, ¹⁰Mayo Clinic, Rochester, MN, ¹¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, ¹²Department of Internal Medicine IV (Nephrology and Hypertension), Innsbruck, Austria
Background/Purpose: ANCA-associated vasculitis (AAV) is a life-threatening disorder characterized by a relapsing-remitting disease course necessitating immunosuppression to control disease activity. Balancing the risks of infection…
Abstract Number: 2601 • ACR Convergence 2023
Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning
kevin cunningham¹, Jaeyun Sung², Benjamin Hur², VINOD GUPTA², Matthew Koster², Cornelia M. Weyand³, David Cuthbertson⁴, Nader Khalidi⁵, Curry Koening⁶, Carol Langford⁷, Carol McAlear⁸, Paul Monach⁹, Larry Moreland¹⁰, Christian Pagnoux¹¹, Rennie Rhee⁸, Philip Seo¹², Peter Merkel⁸ and Kenneth Warrington², ¹University of Minnesota, Minneapolis, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic School of Medicine and Stanford University, Rochester, MN, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Texas Dell Medical School, Austin, TX, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD
Background/Purpose: The availability of diagnostic laboratory tests and specific biomarkers of disease activity for giant cell arteritis (GCA) remains an area of unmet need. The…
Abstract Number: 0157 • ACR Convergence 2023
Discovering the Potential of Digital Biomarkers in the Work Process of the Rheumatology Healthcare Professionals, a Design Thinking Approach; Preliminary Results of the Healthcare Professionals Perspective
patty de Groot¹, Jolanda J. Luime¹, Marc r. Kok², marijn vis¹ and ilja Tchetverikov³, ¹Erasmus Medical Center, Rotterdam, Netherlands, ²Maasstad Hospital, Rotterdam, Netherlands, ³Albert Sweitzer Hospital, Dordrecht, Netherlands
Background/Purpose: During times of social-distancing, in-person outpatient visits were greatly reduced. Health care professionals (HCPs) were dependent on the patient's reported experience of their disease…
Abstract Number: 0548 • ACR Convergence 2023
Clinical and Interferon Biomarkers to Exclude Imminent Autoimmune Disease in ANA Positive Individuals
Md Yuzaiful Md Yusof¹, Sabih Ul-Hassan¹, Zoe Wigston¹, Antonios Psarras², Jack Arnold¹, Lucy Carter³, Paul Emery⁴ and Ed Vital¹, ¹University of Leeds, Leeds, United Kingdom, ²Oxford University, Oxford, United Kingdom, ³University of Leeds, Hartlepool, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Many rheumatologists find it challenging to safely discharge "At-Risk" ANA-positive people at the first visit due to lack of cardinal signs and prediction tools.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].